Nitrolingual (Nitroglycerin) Patent Expiration, LOE Window & CMS Spending

Nitrolingual (Nitroglycerin) by Pohl Boskamp: FDA Orange Book LOE 2029-03-12, 2 AB generics, $45K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPohl Boskamp
FDA Application & PathwayN018705 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-03-12
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$45K
2024 Medicare Part D Spend$27K
2024 Medicaid Spend$17K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel